December 16, 2024
2 min watch
Save
VIDEO: OlympiA trial shows ‘continued benefit’ in breast cancer survival
SAN ANTONIO — In this video, Judy Garber, MD, MPH, discusses the results of the OlympiA trial presented at San Antonio Breast Cancer Symposium.
The study observed patients with BRCA1 or BRCA2 germline pathogenic variants and high-risk HER2-negative breast cancer who received adjuvant olaparib or placebo after neoadjuvant chemotherapy treatment.
“The study shows continued benefit across those variables, including overall survival, most importantly,” Garber, breast oncologist and chief of the division of cancer genetics and prevention at Dana-Farber Cancer Institute, said.
Reference:
- Garber JE, et al. Abstract GS1-09. Presented at: San Antonio Breast Cancer Symposium; Dec. 10-13, 2024; San Antonio.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Garber reports no relevant financial disclosures.